<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582267</url>
  </required_header>
  <id_info>
    <org_study_id>1706-066-1706</org_study_id>
    <nct_id>NCT03582267</nct_id>
  </id_info>
  <brief_title>The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players</brief_title>
  <official_title>The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Christian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Christian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nutrition interventions may present a safe and relatively risk free intervention for
      protection against subconcussive impacts. Docosahexaenoic acid (DHA, 22:6n-3) is the
      principal Omega 3 polyunsaturated fatty acid in the brain, playing an integral role in the
      brain's development and structural integrity. The goal of this study is to determine if
      supplementation with DHA attenuates blood biomarkers of repetitive head trauma linked to
      sub-concussive impacts sustained in rugby participation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentration of neurofilament light protein</measure>
    <time_frame>12 times throughout course of 1 year</time_frame>
    <description>Concentrations of neuronally derived proteins measured in blood</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Head Trauma</condition>
  <arm_group>
    <arm_group_label>Dietary Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docosahexaenoic Acid (DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Docosahexaenoic Acid supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Docosahexaenoic Acid (DHA)</intervention_name>
    <description>Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.</description>
    <arm_group_label>Dietary Supplement</arm_group_label>
    <other_name>Brain Armor DHA Liquid Concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Canadian national rugby athletes on 7s and 15s teams

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Texas Christian Universti</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Christian University</investigator_affiliation>
    <investigator_full_name>Jonathan Oliver</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

